Biotech

Checkpoint Therapeutics (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: James F. Oliviero, President and Chief …

Checkpoint Therapeutics (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “Checkpoint achieved significant financial and pipeline-related milestones in 2017. Most notably, our common stock began trading on The NASDAQ Capital Market in June 2017, and in October, we announced the dosing of the first patient in our Phase 1 trial of our anti-PD-L1 antibody, CK-301. In addition, the FDA granted Orphan Drug Designation to our third-generation EGFR inhibitor, CK-101, for the treatment of EGFR mutation-positive non-small cell lung cancer. As we enter 2018, we believe we are well-positioned to generate initial efficacy data from our clinical trials in support of our planned registration studies to commence in 2019.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20086.10-13.71
TSXV697.70+1.05
DOW31980.68-215.98
S&P 5003991.55-32.34
NASD11679.24-125.76
ASX7075.10+134.10

COMMODITIES

Commodities
Gold1809.24-3.06
Silver21.36+0.15
Copper4.180.00
Palladium1967.50+22.50
Platinum942.00-4.00
Oil110.65+0.16
Heating Oil3.74-0.02
Natural Gas8.09+0.42

DOWNLOAD FREE REPORTS

×